The therapeutic response of approved KRAS inhibitors is not always durable and patients develop resistance frequently. To enhance this durability, the search for KRAS inhibitors in combination with drugs that target downstream or upstream components of RAS is crucial.

Aurobac Therapeutics SAS, a biopharmaceutical company founded by Boehringer Ingelheim Pharma GmbH & Co KG, Biomérieux SA and Evotec SE, has announced its strategy to target bacterial infections, antimicrobial resistance and their consequences in acute hospital settings, such as hospital-acquired and ventilator-associated bacterial pneumonia and sepsis.

Ochre Bio Ltd. has established a partnership with Boehringer Ingelheim Pharma GmbH & Co. KG focused on the discovery and development of novel first-in-class regenerative treatments for chronic liver diseases, such as late-stage metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.

Boehringer Ingelheim Pharma GmbH & Co KG and Sosei Group Corp. have entered a global collaboration and exclusive option-to-license agreement in schizophrenia.

After flying high in 2022, digital therapeutics (DTx) companies crashed to Earth in 2023 and scrambled to identify a path to profitability, or at least continued viability.